% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • checksurshorts checksurshorts Mar 15, 2013 1:10 PM Flag

    Shire's Incoming CEO

    [Established in 2006, privately-held Premacure has pursued clinical development of Premiplex. The protein replacement therapy’s formulation combines recombinant human IGF-1 and a recombinant version of its naturally occurring binding protein, insulin-like growth factor-1 binding protein-3 (IFGBP3).

    During a Phase I clinical trial of the therapy, administration of the investigational protein to preterm infants was generally well tolerated while the presence of IGF-1 was increased to within physiological levels.

    “This investigational protein has the potential to provide a first-in-class treatment that may minimize the development and impact of complications arising from ROP,” Flemming Ornskov, M.D., Shire CEO designate, said in a statement. Dr. Ornskov will become Shire’s CEO on April 30. “We will build on the work that Premacure has done and will apply Shire’s proven ability in developing protein replacement therapies for rare disorders to bring this much-needed therapy to the market.”

    Dr. Ornskov will succeed Angus C. Russell, who in discussing Q4 results with analysts last month mentioned Shire’s ongoing commitment to broadening its product pipeline in rare diseases. The company ended last year undertaking 15 business-development deals and developing three clinical-phase products.]

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.71-0.01(-0.10%)1:09 PMEDT